메뉴 건너뛰기




Volumn 34, Issue 2, 2004, Pages 265-276

Development and validation of a reversed-phase liquid chromatographic method for analysis of degradation products of estradiol in Vagifem® tablets

Author keywords

Degradation products; Estradiol; Pharmaceutical analysis; Placebo interference; Reverse phase chromatography; Sample preparation; Stability indicating

Indexed keywords

16 KETO 17BETA ESTRADIOL; 4 METHYL 17BETA ESTRADIOL; 6 DEHYDRO 17BETA ESTRADIOL; 6 KETO 17BETA ESTRADIOL; 6 KETOESTRONE; 6ALPHA HYDROXY 17BETA ESTRADIOL; 6BETA HYDROXY 17BETA ESTRADIOL; ALPHA 17BETA ESTRADIOL; BETA EQUILENOL; DRUG METABOLITE; ESTRADIOL; ESTRONE; PLACEBO; UNCLASSIFIED DRUG;

EID: 0842330582     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(03)00501-6     Document Type: Article
Times cited : (24)

References (12)
  • 11
    • 84949063371 scopus 로고    scopus 로고
    • Merck & Co., Inc., Rahway, NJ, USA
    • The Merck Index, 13th ed., Merck & Co., Inc., Rahway, NJ, USA.
    • The Merck Index, 13th Ed.
  • 12
    • 84870757941 scopus 로고    scopus 로고
    • Impurities in New Drug Products, ICH secretariate, Geneva, Switzerland
    • ICH Harmonised Tripartite Guideline, Impurities in New Drug Products, ICH secretariate, Geneva, Switzerland.
    • ICH Harmonised Tripartite Guideline


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.